What Is the First-Line Treatment for Cold Urticaria?
Cold urticaria is a cold-triggered physical inducible urticaria presenting with wheals and potentially angioedema following cold exposure. This page outlines the first-line management approach and the clinical goals that define treatment success.
First-Line Approach
Management starts with consistent avoidance of cold exposure alongside regular daily use of a modern 2nd generation H1-antihistamine — with multiple evidence-supported agents available and no single agent preferred over another.
Complete agent selection, dosing guidance, and the full structured regimen are available in the protocol below ↓
Treatment Goals
The target is complete symptom control: a continuous UAS7 of zero with full absence of wheals and angioedema. Adequacy of control is reassessed after 2–4 weeks.
References
DOI: 10.1111/all.15090
- In CIndU, avoidance of specific and definite triggers for the development of signs and symptoms, for example, cold in cold urticaria, can reduce disease activity.
- We recommend a 2nd generation H1-antihistamine as first-line treatment for all types of urticaria.
- We recommend the use of a standard-dosed modern 2nd generation H1-antihistamines as the first-line symptomatic treatment for urticaria.
- Most but not all 2nd generation H1-antihistamines have been tested specifically in urticaria, and evidence supports the use of bilastine, cetirizine, desloratadine, ebastine, fexofenadine, levocetirizine, loratadine, and rupatadine.
- We suggest 2nd generation H1-antihistamines to be taken regularly for the treatment of patients with chronic urticaria.
- The goal of treatment is to treat the disease until it is gone and as efficiently and safely as possible aiming at a continuous UAS7 = 0, complete control and a normalization of quality of life.
- We recommend aiming at complete symptom control in urticaria, considering as much as possible the safety and the quality of life of each individual patient.
View source ↗